Comparison of injectable and oral antipsychotics in relapse rates in a pragmatic 30-month schizophrenia relapse prevention study

Peter F Buckley, Nina R. Schooler, Donald C. Goff, Alex Kopelowicz, John Lauriello, Theo C. Manschreck, Alan Mendelowitz, Del D. Miller, Daniel R. Wilson, Donna Ames, Juan R. Bustillo, John M. Kane, Stephen Warwick Looney

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective: In a pragmatic clinical trial, this study sought t compare relapses among patients receiving either longactin injectable or oral second-generation antipsychotics Methods: PROACTIVE (Preventing Relapse Oral Antipsychotic Compared to Injectables Evaluating Efficacy), a prio 30-month relapse prevention study, compared use of long-Acting injectable second-generation antipsychoti with use of an oral second-generation antipsychotic by 30 patients with schizophrenia or schizoaffective disorder an found similar rates of first relapse between groups (42% wit injectable medication, 32% with oral medication). This stud examined subsequent relapses among patients who ha relapsed in PROACTIVE and who continued in treatment follow-up, or both Results: Thirty-Two patients (11%) experienced two relapses and 13 patients (4%) had three relapses. Neither rate of relaps nor time to successive relapses differed betwee treatment groups Conclusions: There was an impressively low rate of subsequen relapses in this pragmatic clinical trial. Becaus all patients had a clinic visit according to the biweekl long-Acting injectable medication administration schedule frequent contact may have contributed to low relapse rates Maintaining frequent clinical contact may be a valid psychosocia relapse prevention treatment.

Original languageEnglish (US)
Pages (from-to)1370-1372
Number of pages3
JournalPsychiatric Services
Volume67
Issue number12
DOIs
StatePublished - Dec 1 2016

Fingerprint

Secondary Prevention
Antipsychotic Agents
Schizophrenia
Recurrence
Injections
Pragmatic Clinical Trials
Wit and Humor
Ambulatory Care
Psychotic Disorders
Appointments and Schedules
Therapeutics

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Comparison of injectable and oral antipsychotics in relapse rates in a pragmatic 30-month schizophrenia relapse prevention study. / Buckley, Peter F; Schooler, Nina R.; Goff, Donald C.; Kopelowicz, Alex; Lauriello, John; Manschreck, Theo C.; Mendelowitz, Alan; Miller, Del D.; Wilson, Daniel R.; Ames, Donna; Bustillo, Juan R.; Kane, John M.; Looney, Stephen Warwick.

In: Psychiatric Services, Vol. 67, No. 12, 01.12.2016, p. 1370-1372.

Research output: Contribution to journalArticle

Buckley, PF, Schooler, NR, Goff, DC, Kopelowicz, A, Lauriello, J, Manschreck, TC, Mendelowitz, A, Miller, DD, Wilson, DR, Ames, D, Bustillo, JR, Kane, JM & Looney, SW 2016, 'Comparison of injectable and oral antipsychotics in relapse rates in a pragmatic 30-month schizophrenia relapse prevention study', Psychiatric Services, vol. 67, no. 12, pp. 1370-1372. https://doi.org/10.1176/appi.ps.201500466
Buckley, Peter F ; Schooler, Nina R. ; Goff, Donald C. ; Kopelowicz, Alex ; Lauriello, John ; Manschreck, Theo C. ; Mendelowitz, Alan ; Miller, Del D. ; Wilson, Daniel R. ; Ames, Donna ; Bustillo, Juan R. ; Kane, John M. ; Looney, Stephen Warwick. / Comparison of injectable and oral antipsychotics in relapse rates in a pragmatic 30-month schizophrenia relapse prevention study. In: Psychiatric Services. 2016 ; Vol. 67, No. 12. pp. 1370-1372.
@article{c178a35b57e34c5095d30478601e97b4,
title = "Comparison of injectable and oral antipsychotics in relapse rates in a pragmatic 30-month schizophrenia relapse prevention study",
abstract = "Objective: In a pragmatic clinical trial, this study sought t compare relapses among patients receiving either longactin injectable or oral second-generation antipsychotics Methods: PROACTIVE (Preventing Relapse Oral Antipsychotic Compared to Injectables Evaluating Efficacy), a prio 30-month relapse prevention study, compared use of long-Acting injectable second-generation antipsychoti with use of an oral second-generation antipsychotic by 30 patients with schizophrenia or schizoaffective disorder an found similar rates of first relapse between groups (42{\%} wit injectable medication, 32{\%} with oral medication). This stud examined subsequent relapses among patients who ha relapsed in PROACTIVE and who continued in treatment follow-up, or both Results: Thirty-Two patients (11{\%}) experienced two relapses and 13 patients (4{\%}) had three relapses. Neither rate of relaps nor time to successive relapses differed betwee treatment groups Conclusions: There was an impressively low rate of subsequen relapses in this pragmatic clinical trial. Becaus all patients had a clinic visit according to the biweekl long-Acting injectable medication administration schedule frequent contact may have contributed to low relapse rates Maintaining frequent clinical contact may be a valid psychosocia relapse prevention treatment.",
author = "Buckley, {Peter F} and Schooler, {Nina R.} and Goff, {Donald C.} and Alex Kopelowicz and John Lauriello and Manschreck, {Theo C.} and Alan Mendelowitz and Miller, {Del D.} and Wilson, {Daniel R.} and Donna Ames and Bustillo, {Juan R.} and Kane, {John M.} and Looney, {Stephen Warwick}",
year = "2016",
month = "12",
day = "1",
doi = "10.1176/appi.ps.201500466",
language = "English (US)",
volume = "67",
pages = "1370--1372",
journal = "Psychiatric Services",
issn = "1075-2730",
publisher = "American Psychiatric Association",
number = "12",

}

TY - JOUR

T1 - Comparison of injectable and oral antipsychotics in relapse rates in a pragmatic 30-month schizophrenia relapse prevention study

AU - Buckley, Peter F

AU - Schooler, Nina R.

AU - Goff, Donald C.

AU - Kopelowicz, Alex

AU - Lauriello, John

AU - Manschreck, Theo C.

AU - Mendelowitz, Alan

AU - Miller, Del D.

AU - Wilson, Daniel R.

AU - Ames, Donna

AU - Bustillo, Juan R.

AU - Kane, John M.

AU - Looney, Stephen Warwick

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Objective: In a pragmatic clinical trial, this study sought t compare relapses among patients receiving either longactin injectable or oral second-generation antipsychotics Methods: PROACTIVE (Preventing Relapse Oral Antipsychotic Compared to Injectables Evaluating Efficacy), a prio 30-month relapse prevention study, compared use of long-Acting injectable second-generation antipsychoti with use of an oral second-generation antipsychotic by 30 patients with schizophrenia or schizoaffective disorder an found similar rates of first relapse between groups (42% wit injectable medication, 32% with oral medication). This stud examined subsequent relapses among patients who ha relapsed in PROACTIVE and who continued in treatment follow-up, or both Results: Thirty-Two patients (11%) experienced two relapses and 13 patients (4%) had three relapses. Neither rate of relaps nor time to successive relapses differed betwee treatment groups Conclusions: There was an impressively low rate of subsequen relapses in this pragmatic clinical trial. Becaus all patients had a clinic visit according to the biweekl long-Acting injectable medication administration schedule frequent contact may have contributed to low relapse rates Maintaining frequent clinical contact may be a valid psychosocia relapse prevention treatment.

AB - Objective: In a pragmatic clinical trial, this study sought t compare relapses among patients receiving either longactin injectable or oral second-generation antipsychotics Methods: PROACTIVE (Preventing Relapse Oral Antipsychotic Compared to Injectables Evaluating Efficacy), a prio 30-month relapse prevention study, compared use of long-Acting injectable second-generation antipsychoti with use of an oral second-generation antipsychotic by 30 patients with schizophrenia or schizoaffective disorder an found similar rates of first relapse between groups (42% wit injectable medication, 32% with oral medication). This stud examined subsequent relapses among patients who ha relapsed in PROACTIVE and who continued in treatment follow-up, or both Results: Thirty-Two patients (11%) experienced two relapses and 13 patients (4%) had three relapses. Neither rate of relaps nor time to successive relapses differed betwee treatment groups Conclusions: There was an impressively low rate of subsequen relapses in this pragmatic clinical trial. Becaus all patients had a clinic visit according to the biweekl long-Acting injectable medication administration schedule frequent contact may have contributed to low relapse rates Maintaining frequent clinical contact may be a valid psychosocia relapse prevention treatment.

UR - http://www.scopus.com/inward/record.url?scp=85000420256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85000420256&partnerID=8YFLogxK

U2 - 10.1176/appi.ps.201500466

DO - 10.1176/appi.ps.201500466

M3 - Article

VL - 67

SP - 1370

EP - 1372

JO - Psychiatric Services

JF - Psychiatric Services

SN - 1075-2730

IS - 12

ER -